It started as a side effect—and turned into a global phenomenon. In the development of a drug to treat type 2 diabetes, researchers discovered something unexpected: the active ingredient not only regulated blood sugar but also significantly reduced body weight. Suddenly, a new blockbuster industry was born. The surge began in 2018 with the U.S. debut of Ozempic, a GLP-1 receptor agonist by Novo Nordisk. Though not initially approved for weight loss, it quickly gained traction off-label as patients reported dramatic drops in weight. Novo Nordisk capitalized on this demand with Wegovy in 2021, a higher-dose version of semaglutide approved…